Nektar Therapeutics (NASDAQ:NKTR) Stock Has Consensus Price Target of $138.50 According to Brokerages

Shares of Nektar Therapeutics (NASDAQ:NKTR) have been assigned a consensus rating of “Moderate Buy” from the thirteen ratings firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, two have given a hold rating, nine have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $138.50.

A number of equities research analysts have recently weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Nektar Therapeutics in a report on Friday, August 28th. Wedbush reduced their price target on Nektar Therapeutics from $80.00 to $50.00 and set a “neutral” rating on the stock in a research report on Wednesday, September 23rd. TD Cowen upgraded Nektar Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th. BTIG Research restated a “buy” rating and issued a $178.00 price target on shares of Nektar Therapeutics in a research report on Friday, September 25th. Finally, JPMorgan Chase & Co. started coverage on Nektar Therapeutics in a research note on Friday, August 21st. They issued a “neutral” rating and a $65.00 price target for the company.

Nektar Therapeutics Stock Performance

NASDAQ NKTR opened at $40.26 on Thursday. The stock has a market cap of $1.37 billion, a PE ratio of -6.01 and a beta of 1.26. The firm has a 50-day moving average of $67.74 and a 200-day moving average of $70.34. Nektar Therapeutics has a 52-week low of $33.40 and a 52-week high of $109.00.

Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported ($1.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.97) by $0.74. The company had revenue of $10.13 million during the quarter, compared to analysts’ expectations of $10.43 million. Nektar Therapeutics had a negative return on equity of 37.87% and a negative net margin of 287.84%. As a group, analysts predict that Nektar Therapeutics will post -8.16 EPS for the current fiscal year.

Insider Buying and Selling at Nektar Therapeutics

In other Nektar Therapeutics news, CEO Howard Robin sold 418 shares of the firm’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $71.98, for a total value of $30,087.64. Following the sale, the chief executive officer owned 54,627 shares of the company’s stock, valued at approximately $3,932,051.46. This trade represents a 0.76% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 2.50% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. KBC Group NV bought a new position in Nektar Therapeutics in the first quarter valued at about $52,000. State of Wyoming acquired a new stake in Nektar Therapeutics in the 1st quarter valued at $67,000. Allspring Global Investments Holdings LLC acquired a new position in Nektar Therapeutics during the 1st quarter valued at about $209,000. Great Lakes Advisors LLC acquired a new position in Nektar Therapeutics during the 2nd quarter valued at about $206,000. Finally, Pale Fire Capital SE bought a new position in Nektar Therapeutics during the 2nd quarter valued at $234,000. Institutional investors and hedge funds own 75.88% of the company’s stock.

Nektar Therapeutics Company Profile

Nektar Therapeutics is a biopharmaceutical company focused on discovering and developing medicines that use the body’s immune system to treat cancer and autoimmune diseases. The company’s research programs are based on proprietary drug-design and immunology technologies intended to improve the activity, targeting, or dosing of therapeutic agents.

Nektar’s pipeline has included NKTR-255, an investigational interleukin-15 receptor agonist designed to activate natural killer cells and support antitumor immune responses.